Cidara Therapeutics, Inc.
CDTXDelisted Jan 7, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001610618
Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.
13F holders, Q1 2025
Institutional positions in Cidara Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 46
- +6 vs. Q4 2024
- Shares held
- 9.56M
- +2.69M (+39.1%) vs. Q4 2024
- Total value
- $205.9M
- +$22.3M (+12.1%) vs. Q4 2024
- New holders
- 8
- 19 more added
- Sold out
- 2
- 9 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CDTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 255 | $7.36B |
| Q3 2025 | 173 | $3.11B |
| Q2 2025 | 109 | $1.26B |
| Q1 2025 | 46 | $205.9M |
| Q4 2024 | 40 | $183.6M |
| Q3 2024 | 27 | $35.6M |
| Q2 2024 | 26 | $16.9M |
| Q1 2024 | 50 | $20.3M |
| Q4 2023 | 51 | $18.4M |
| Q3 2023 | 52 | $22.7M |
| Q2 2023 | 52 | $29.7M |
| Q1 2023 | 54 | $34.4M |
| Q4 2022 | 42 | $20.2M |
| Q3 2022 | 42 | $17.1M |
| Q2 2022 | 46 | $13.3M |
| Q1 2022 | 44 | $25.2M |
| Q4 2021 | 53 | $39.5M |
| Q3 2021 | 50 | $42.1M |
| Q2 2021 | 55 | $40.5M |
| Q1 2021 | 62 | $56.6M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Cidara Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 6 | $129 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 17 | $366 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 20 | $431 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 28 | $603 | 0.00% | +28 | New |
| Allworth Financial LP | 40 | $860 | 0.00% | 00.0% | Unchanged |
| Avion Wealth | 250 | $6.00K | 0.00% | 00.0% | Unchanged |
| Point72 (DIFC) Ltd | 469 | $10.1K | 0.00% | +271+136.9% | Added |
| Citigroup Inc | 577 | $12.4K | 0.00% | −7,007−92.4% | Reduced |
| Tower Research Capital LLC (TRC) | 933 | $20.1K | 0.00% | +933 | New |
| Point72 Asia (Singapore) Pte. Ltd. | 1,552 | $33.4K | 0.01% | −533−25.6% | Reduced |
| Morgan Stanley | 8,217 | $177.0K | 0.00% | +5,787+238.1% | Added |
| American Century Companies Inc | 10,409 | $224.2K | 0.00% | +10,409 | New |
| West Michigan Advisors, LLC | 13,500 | $290.8K | 0.10% | +13,500 | New |
| Alethea Capital Management, LLC | 14,311 | $308.3K | 0.23% | 00.0% | Unchanged |
| Sphera Funds Management Ltd. | 17,128 | $368.9K | 0.09% | +17,128 | New |
| Omers Administration Corp | 19,300 | $415.7K | 0.00% | +6,700+53.2% | Added |
| ADAR1 Capital Management, LLC | 20,938 | $451.0K | 0.09% | −4,000−16.0% | Reduced |
| Schonfeld Strategic Advisors LLC | 21,124 | $455.0K | 0.00% | −28,433−57.4% | Reduced |
| State Street Corp | 22,576 | $486.3K | 0.00% | +3,500+18.3% | Added |
| Bank of America Corp | 27,501 | $592.4K | 0.00% | +27,451+54,902.0% | Added |
| Jane Street Group, LLC | 27,849 | $599.9K | 0.00% | +15,135+119.0% | Added |
| Northern Trust Corp | 33,560 | $722.9K | 0.00% | −397−1.2% | Reduced |
| Goldman Sachs Group Inc | 42,143 | $907.8K | 0.00% | +28,273+203.8% | Added |
| BlackRock, Inc. | 52,896 | $1.14M | 0.00% | −2,629−4.7% | Reduced |
| Geode Capital Management, LLC | 54,983 | $1.18M | 0.00% | +1,915+3.6% | Added |
| 5AM Venture Management, LLC | 56,725 | $1.22M | 0.46% | 00.0% | Unchanged |
| Millennium Management LLC | 63,580 | $1.37M | 0.00% | +27,620+76.8% | Added |
| UBS Group AG | 66,813 | $1.44M | 0.00% | +19,942+42.5% | Added |
| Boothbay Fund Management, LLC | 79,081 | $1.70M | 0.06% | +63,480+406.9% | Added |
| Renaissance Technologies LLC | 92,517 | $1.99M | 0.00% | −3,100−3.2% | Reduced |
| Checkpoint Capital L.P. | 104,380 | $2.25M | 1.23% | −92,569−47.0% | Reduced |
| Point72 Asset Management, L.P. | 113,855 | $2.45M | 0.01% | +107,707+1,751.9% | Added |
| Standard Life Aberdeen plc | 120,879 | $2.60M | 0.01% | +120,879 | New |
| Acuta Capital Partners, LLC | 125,708 | $2.71M | 3.14% | +71,235+130.8% | Added |
| Ikarian Capital, LLC | 248,940 | $5.36M | 1.75% | +195,000+361.5% | Added |
| Citadel Advisors LLC | 287,775 | $6.20M | 0.01% | +287,775 | New |
| Susquehanna International Group, LLP | 342,476 | $7.38M | 0.01% | +299,853+703.5% | Added |
| Vestal Point Capital, LP | 504,542 | $10.9M | 0.78% | +504,542 | New |
| Vanguard Group Inc | 509,576 | $11.0M | 0.00% | +292,072+134.3% | Added |
| Vivo Capital, LLC | 684,276 | $14.7M | 1.95% | +13,676+2.0% | Added |
| Bain Capital Life Sciences Investors, LLC | 703,080 | $15.1M | 2.24% | 00.0% | Unchanged |
| BVF Inc | 924,642 | $19.9M | 0.81% | −168,154−15.4% | Reduced |
| Adage Capital Partners GP, L.L.C. | 990,000 | $21.3M | 0.04% | +620,046+167.6% | Added |
| TCG Crossover Management, LLC | 1,005,901 | $21.7M | 2.96% | 00.0% | Unchanged |
| VR Adviser, LLC | 1,051,518 | $22.6M | 1.93% | +285,795+37.3% | Added |
| Ra Capital Management, L.P. | 1,092,796 | $23.5M | 0.39% | 00.0% | Unchanged |
| StemPoint Capital LP | 0 | $0 | 0.00% | −47,642−100.0% | Sold out |
| Manchester Capital Management LLC | 0 | $0 | 0.00% | −470−100.0% | Sold out |